Veradermics (MANE) Prepaid Assets (2024 - 2026)

Veradermics posted quarterly Prepaid Assets of $602000.0 for Q1 2026, up 96.09% on a QoQ basis from $307000.0 in Q4 2025.

Veradermics (MANE) has 3 years of Prepaid Assets data on file, last reported at $602000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Prepaid Assets changed N/A year-over-year to $602000.0; the trailing twelve-month figure through Mar 2026 stood at $602000.0 (changed N/A YoY), and the FY2025 full-year result was $307000.0, up 707.89% from the prior year.
  • Prepaid Assets for Q1 2026 stood at $602000.0, up from $307000.0 in the prior quarter.
  • Across five years, Prepaid Assets topped out at $602000.0 in Q1 2026 and bottomed at $38000.0 in Q4 2024.
  • The 3-year median for Prepaid Assets is $307000.0 (2025), against an average of $315666.7.
  • Peak annual rise in Prepaid Assets reached 707.89% in 2025, while the deepest fall reached 707.89% in 2025.
  • A 3-year view of Prepaid Assets shows it stood at $38000.0 in 2024, then jumped by 707.89% to $307000.0 in 2025, then soared by 96.09% to $602000.0 in 2026.
  • The last three Prepaid Assets figures came in at $602000.0 (Q1 2026), $307000.0 (Q4 2025), and $38000.0 (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Veradermics 2.29 Bn 2.29 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 602,000.00
Dec 31, 2025 307,000.00
Dec 31, 2024 38,000.00